myCME™ is a medical education website that delivers certified CME/CE activities that meet the continuing professional development needs of clinicians worldwide. The site’s hundreds of available certified activities spanning dozens of clinical topics are constructed through partnerships with many of the country’s leading academic institutions, medical societies and associations, and accredited providers.
myCME Podcasts
Claim This Podcastby myCME
3.0(1 reviews)
4 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇺🇸
Podcast Overview
myCME™ is a medical education website that delivers certified CME/CE activities that meet the continuing professional development needs of clinicians worldwide. The site’s hundreds of available certified activities spanning dozens of clinical topics are constructed through partnerships with many of the country’s leading academic institutions, medical societies and associations, and accredited providers.
Language
🇺🇲
Publishing Since
4/5/2022
1 verified contact email on file for myCME Podcasts
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 8, 2022
Strengthening the Patient-Provider Therapeutic Alliance In Obesity Care: Minimizing Stigma and Increasing Patient Engagement—Obesity Series Podcast 3
<p><strong>Important: </strong>After listening to the podcast, you will need to visit myCME to complete the post-assessment and evaluation and to claim your credits and certificate for this activity. Please go to <a href="http://www.mycme.com/obesity3">www.mycme.com/obesity3</a> on any browser to complete the activity.</p><p> </p><p><strong>Description</strong></p><p>Poorer health outcomes among individuals with overweight and obesity are made more likely and are being exacerbated by their experiencing weight-related stigma in healthcare settings, resulting in shorter office visits, less likelihood of preventive health screening, and fewer appropriate medical treatments.</p><p>In this audio activity, Dr. Robert Kushner and Dr. Pamela Kushner review some of the potential biases that healthcare providers may unknowingly harbor related to obesity, and how these perceptions can negatively impact patient care. The faculty provide practical strategies that clinicians can implement to improve communication with their patients with obesity, and discuss methods for keeping patients engaged in obesity care over the long-term.</p><p>This activity is designed for primary care providers (MDs/DOs, PAs, NPs), endocrinologists, cardiologists, dieticians/nutritionist, pharmacists, and other members of the multidisciplinary obesity care team.</p><p>This activity is supported by an educational grant from Novo Nordisk.</p><p>At the conclusion of this activity, participants should be better able to:</p><ul><li><strong>Implement</strong> practical interventions to destigmatize obesity, surmount barriers to maintenance of weight loss over the long term, and enhance patient engagement</li></ul><p><strong>Faculty</strong></p><p><strong>Pamela Kushner, MD, FAAFP</strong><br /><strong>Clinical Professor</strong><br /><strong>University of California at Irvine</strong><br /><strong>Irvine, CA</strong></p><p><strong>Dr. Pamela Kushner is a consultant for Abbott, Intuity Medical, Inc., and Phathom Pharmaceuticals and is speaker and consultant for AstraZeneca, Eli Lilly and Company, GSK, and Janssen Pharmaceuticals, Inc.</strong></p><p><strong>Robert F. Kushner, MD, MS, FACP, DABOM</strong><br /><strong>Professor, Departments of Medicine and Medical Education</strong><br /><strong>Northwestern University Feinberg School of Medicine</strong><br /><strong>Director, Center for Lifestyle Medicine, Northwestern Medicine</strong><br /><strong>Chicago, IL</strong></p><p><strong>Dr. Robert Kushner is on the advisory board of Novo Nordisk and WW International, Inc., is a consultant for Pfizer Inc. and Altimmune, and has received research funding from Epitomee Medical.</strong></p><p><strong>All of the relevant financial relationships listed for these individuals have been mitigated.</strong></p>
July 7, 2022
Exploring the Full Spectrum of Pharmacologic Agents for Treating Obesity: Pairing Each Patient With the Most Effective Option—Obesity Series Podcast 2
<p><strong>Important: </strong>After listening to the podcast, you will need to visit myCME to complete the post-assessment and evaluation and to claim your credits and certificate for this activity. Please go to <a href="http://www.mycme.com/obesity2">www.mycme.com/obesity</a>2 on any browser to complete the activity.</p><p> </p><p><strong>Description</strong></p><p>In June 2021, the FDA approved a once-weekly, subcutaneous formulation of the GLP-1 receptor agonist semaglutide for chronic weight management in adults who are overweight or obese and have at least one weight-related comorbidity, making it the first new anti-obesity drug approved in the U.S. since 2014. While pharmacotherapy is an important tool for obesity management, these modalities must be appropriately used, based on the available evidence, established indications, and guidelines for therapeutic outcomes assessment.</p><p>In this audio activity, Dr. Pamela Kushner and Dr. Ken Fujioka discuss appropriate obesity treatment goals individualized to the needs of each patient and review the reasons that patients frequently regain weight lost via lifestyle interventions. The faculty take a closer look at the spectrum of available pharmacologic options for obesity treatment and discuss how some of these agents directly target the pathophysiology that underlies the disease, resulting in meaningful weight loss.</p><p>This activity is designed for primary care providers (MDs/DOs, PAs, NPs), endocrinologists, cardiologists, dieticians/nutritionist, pharmacists, and other members of the multidisciplinary obesity care team.</p><p>This activity is supported by an educational grant from Novo Nordisk.</p><p>At the conclusion of this activity, participants should be better able to:</p><ul><li>Describe the underlying pathophysiology of obesity and metabolic adaptations to weight loss</li><li>Apply the most recent evidence-based guidelines for the identification and individualized treatment of obesity in adults and other populations</li><li>Review efficacy, safety, and tolerability data for the full array of available and emerging pharmacotherapies to achieve and maintain clinically meaningful long-term weight loss</li></ul><p><strong>Faculty</strong></p><p><strong>Pamela Kushner, MD, FAAFP</strong><br /><strong>Clinical Professor</strong><br /><strong>University of California at Irvine</strong><br /><strong>Irvine, CA</strong></p><p><strong>Dr. Kushner is a consultant for Abbott, Intuity Medical, Inc., and Phathom Pharmaceuticals and is speaker and consultant for AstraZeneca, Eli Lilly and Company, GSK, and Janssen Pharmaceuticals, Inc.</strong></p><p><strong>Ken Fujioka, MD</strong><br /><strong>Director Nutrition and Metabolic Research</strong><br /><strong>Scripps Clinic</strong><br /><strong>Division of Diabetes and Endocrine</strong><br /><strong>San Diego, CA</strong></p><p><strong>Dr. Fujioka is a consultant for Novo Nordisk, Gelesis, Nalpropion Pharmaceuticals LLC, Amgen Inc., KVK Tech, Inc, Phenomix Sciences, LLC, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Rhythm Pharmaceuticals, Inc., and Takeda Pharmaceuticals. He is also on the speakers’ bureaus of Novo Nordisk, Nalpropion, Rhythm, and Takeda.</strong></p><p><strong>All of the relevant financial relationships listed for these individuals have been mitigated.</strong></p>
June 10, 2022
One Step at a Time: Applying the Latest Data About Obesity Identification and Management to Real-World Practice—Obesity Series Podcast 1
<p><strong>Important: </strong>After listening to the podcast, you will need to visit myCME to complete the post-assessment and evaluation and to claim your credits and certificate for this activity. Please go to <a href="http://www.mycme.com/obesity1">www.mycme.com/obesity1</a> on any browser to complete the activity.</p><p> </p><p>Despite widespread awareness of the potential long-term health consequences of obesity, this chronic disease is not often managed with the determination and urgency that it requires. Poor health outcomes among obese individuals are often exacerbated by weight-related stigma in healthcare settings, as well as lack of knowledge about the safety and efficacy of novel therapeutic options.</p><p>This audio activity discusses the importance of early and sustained interventions for patients with obesity, as well as updated guidelines for identification and long-term management. The expert faculty review common obesity comorbidities as well as novel strategies to help patients overcome the metabolic adaptations that make it challenging to keep weight off with lifestyle interventions alone.</p><p>This activity is designed for primary care providers (MDs/DOs, PAs, NPs), endocrinologists, cardiologists, dieticians/nutritionist, pharmacists, and other members of the multidisciplinary obesity care team.</p><p>This activity is supported by an educational grant from Novo Nordisk.</p><p>At the conclusion of this activity, participants should be better able to:</p><ul><li>Describe the underlying pathophysiology of obesity and metabolic adaptations to weight loss</li><li>Apply the most recent evidence-based guidelines for the identification and individualized treatment of obesity in adults and other populations</li></ul><p> </p><p><strong>Faculty</strong></p><p><strong>Deepak L. Bhatt, MD, MPH</strong><br /><strong>Executive Director of Interventional Cardiovascular Programs</strong><br /><strong>Brigham and Women’s Hospital Heart & Vascular Center</strong><br /><strong>Professor of Medicine</strong><br /><strong>Harvard Medical School</strong><br /><strong>Boston, MA</strong></p><p><strong>Dr. Bhatt has received researching funding from Abbott, Afimmune Limited, Amarin Pharma, Inc., Amgen Inc., AstraZeneca, Bayer, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Cardax Inc., CellProthera, Cereno Scientific, Chiesi USA, Inc., CSL Behring LLC, Eisai, Inc., Eli Lilly and Company, Ethicon Inc., Faraday Pharmaceuticals, Ferring Pharmaceuticals Inc., Forest Laboratories Inc., Fractyl Health, Inc., Garmin International, Inc., HLS Therapeutics, Inc., Idorsia Pharmaceuticals Ltd., Ironwood Pharmaceuticals, Inc., Ischemix, Inc., Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Medtronic PLC, MyoKardia Inc., NirvaMed, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk, Owkin, Inc., Pfizer Inc., PhaseBio Pharmaceuticals, PLx Pharma Inc., Regeneron Pharmaceuticals, Inc., Roche Diagnostics Corp. (F. Hoffman-La Roche Ltd), Sanofi, Stasys Medical, Synaptic, The Medicines Company, and 89bio, Inc.</strong></p><p><strong>Robert F. Kushner, MD, MS, FACP, DABOM</strong><br /><strong>Professor, Departments of Medicine and Medical Education</strong><br /><strong>Northwestern University Feinberg School of Medicine</strong><br /><strong>Director, Center for Lifestyle Medicine, Northwestern Medicine</strong><br /><strong>Chicago, IL</strong></p><p><strong>Dr. Kushner is on the advisory board of Novo Nordisk and WW International, Inc., is a consultant for Pfizer Inc. and Altimmune, and has received research funding from Epitomee Medical.</strong></p><p><strong>All of the relevant financial relationships listed for these individuals has been mitigated.</strong></p>
4 total episodes available
Deep-dive analytics for myCME Podcasts
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is myCME Podcasts?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
No, this podcast does not typically feature guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.